Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
March 21 2022 - 8:00AM
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage
biopharmaceutical company focused on innovative therapeutics to
treat orphan autoimmune and inflammatory diseases where complement
(C5) and/or leukotriene (LTB4) systems are implicated, today
announced that Professor Virginia Calder, Professor of Ocular
Inflammation, The Institute of Ophthalmology, UCL and Moorfields
Eye Hospital, London, UK and Akari Therapeutics will be giving an
oral and poster presentation at the ARVO 2022 Annual Meeting from
Akari’s programs in age-related macular degeneration (AMD) /
Geographic Atrophy (GA) using long acting PAS-nomacopan and from
its surface of the eye studies with topical nomacopan.
“We very much look forward to presenting data on our eye
programs at ARVO. There is a significant unmet need in back of the
eye diseases including dry AMD and uveitis as well as for surface
of the eye inflammatory conditions. PAS-nomacopan and nomacopan
inhibit both the complement and leukotriene pathways which we
believe represents a unique treatment option for these sight
threatening and difficult to treat diseases,” said Clive
Richardson, Chief Executive Officer of Akari Therapeutics.
Dr. Wynne Weston-Davies, Medical Director, Akari Therapeutics,
will present during the AMD and Diabetic Retinopathy session on the
development of Akari’s long acting PAS-nomacopan molecule for use
in retinal diseases. The poster details are:
Presentation Title: Development of
long-acting PAS-nomacopan for treatment of GA and other retinal
diseasesSession Type: Poster
SessionSession: AMD and Diabetic
RetinopathyDate and Time: May 1, 2022, 12:15
p.m. - 2:15 p.m.Location: Poster Hall (Denver
Convention Center)
Professor Virginia Calder will present during the Antimicrobial
and Immunomodulator Therapeutics session on topical nomacopan in
allergic conjunctival disease. The presentation details
are:Presentation Title: Comparison of topical
Nomacopan, a dual Complement and leukotriene LTB4 inhibitor, with
dexamethasone in downregulating experimental allergic conjunctival
disease (EAC)Session Type: Oral
SessionPresentation Number: 1094
Session: Antimicrobial and Immunomodulator
Therapeutics Session Date and Time: May 2, 2022,
10:00 a.m. - 12:00 p.m. Presentation Time: 10:17
a.m. - 10:34 a.m. Location: Room: 601/603 (Denver
Convention Center)
The oral presentation and poster will be made available in the
Presentations section of the Akari Investor Relations site at
www.investor.akaritx.com following its presentations.
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing
inhibitors of acute and chronic inflammation, specifically for the
treatment of rare and orphan diseases, in particular those where
the complement (C5) or leukotriene (LTB4) systems, or both
complement and leukotrienes together, play a primary role in
disease progression. Akari's lead drug candidate, nomacopan, is a
C5 complement inhibitor that also independently and specifically
inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently
being clinically evaluated in four areas: bullous pemphigoid (BP),
thrombotic microangiopathy (TMA), as well as programs in the eye
and lung.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: needs for additional capital to
fund our operations, our ability to continue as a going concern;
uncertainties of cash flows and inability to meet working capital
needs; an inability or delay in obtaining required regulatory
approvals for Nomacopan and any other product candidates, which may
result in unexpected cost expenditures; our ability to obtain
orphan drug designation in additional indications; risks inherent
in drug development in general; uncertainties in obtaining
successful clinical results for Nomacopan and any other product
candidates and unexpected costs that may result therefrom;
difficulties enrolling patients in our clinical trials; our ability
to enter into collaborative, licensing, and other commercial
relationships and on terms commercially reasonable to us; failure
to realize any value of Nomacopan and any other product candidates
developed and being developed in light of inherent risks and
difficulties involved in successfully bringing product candidates
to market; inability to develop new product candidates and support
existing product candidates; the approval by the U.S. Food and Drug
Administration (FDA) and European Medicines Agency (EMA) and any
other similar foreign regulatory authorities of other competing or
superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for Nomacopan may not
be as large as expected; risks associated with the impact of the
COVID-19 pandemic; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; unexpected cost
increases and pricing pressures and risks and other risk factors
detailed in our public filings with the Securities and Exchange
Commission (SEC), including our most recently filed Annual Report
on Form 20-F filed with the SEC. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
For more information
Investor Contact:Peter VozzoICR Westwicke(443)
213-0505peter.vozzo@westwicke.com
Media Contact:Sukaina Virji/ Maya BennisonConsilium Strategic
CommunicationsAkari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2024 to May 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From May 2023 to May 2024